Opinion|Videos|November 17, 2026

Individualizing Third-Line Treatment in mCRC

Building a third-line treatment framework starts with molecular profile and available targeted options, but ultimately rests on patient-centered judgment about goals, tolerance, and realistic expected benefit.

This episode, “Individualizing Third-Line Treatment in mCRC,” features the panel examining how clinicians integrate molecular findings, prior therapy, and patient-specific factors when choosing among later-line options. Dr. Strickler describes entry into the third-line setting as a point where treatment resistance is increasing and the balance between benefit and toxicity becomes more challenging. His first step is to review the tumor’s molecular profile and identify any remaining targeted treatment opportunities. Patients with KRAS G12C mutations or HER2 amplification who have not yet received an appropriate targeted therapy may still have a biomarker-driven option available. Although he generally prefers to introduce targeted therapies earlier, some patients reach third line without having received them. For patients without an actionable target, treatment selection becomes more dependent on patient goals and prior treatment experience. Trifluridine and tipiracil plus bevacizumab is commonly used, while fruquintinib and other later-line therapies may be considered for selected patients.

Dr. Kazmi emphasizes the importance of performance status, organ function, prior toxicity, and the patient’s overall experience with treatment. He also highlights clinical trial participation, including early-phase studies, as an important consideration in the third-line setting. The discussion acknowledges that not every patient will want or benefit from continued third- or fourth-line therapy. Patient preferences and quality-of-life priorities remain central to decision-making.

In the next episode, “Unmet Needs in Third-Line mCRC Treatment,” the panel identifies the remaining limitations of later-line therapy and the advances needed to improve outcomes.

Related to this article